Company news
Ocular Therapeutix, Inc. news in 2025
Ocular Therapeutix, Inc.'s news releases, calls and decks from 2025, newest first.
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
December 7, 2025
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
November 23, 2025
Ocular Therapeutix™ to Participate in November and December Investor Conferences
November 11, 2025
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
November 3, 2025
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
November 3, 2025
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
October 27, 2025
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
October 6, 2025
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint
September 29, 2025
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
September 29, 2025
Ocular Therapeutix™ to Host Investor Day on September 30, 2025
September 7, 2025
Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences
August 26, 2025
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
August 11, 2025
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
August 4, 2025
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
July 28, 2025
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
June 25, 2025
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
June 15, 2025
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
May 27, 2025
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
May 13, 2025
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
May 4, 2025
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
April 28, 2025
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
April 27, 2025
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
March 30, 2025
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights
March 2, 2025
Ocular Therapeutix™ to Present at Two Investor Conferences in March
February 24, 2025
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
February 23, 2025
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
February 2, 2025
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
January 13, 2025
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation
January 7, 2025